Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gastrointestinal 1Dermatologic 1Classical hematology 1

Conditions

Nasopharyngeal Carcinoma 3Epstein-Barr Virus Infections 2Stomach Neoplasms 1Recurrence 1Neoplasm Metastasis 1Multiple Acyl Coenzyme A Dehydrogenase Deficiency 1Lymphoproliferative Disorders 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Hodgkin Disease 1Head and Neck Neoplasms 1

Interventions

fludarabine phosphate 2fludarabine 2Polymerase Chain Reaction 2Cyclophosphamide 2pembrolizumab 1motexafin gadolinium 1fialuridine 1cc-486 1belinostat 1Vorinostat 1Valganciclovir 1Specimen Handling 1Ritonavir 1Radiotherapy 1Psychology, Positive 1Nivolumab 1Nicotine 1Nelfinavir 1Microarray Analysis 1Methods 1Magnetic Resonance Spectroscopy 1Interleukin-2 1Injections, Subcutaneous 1Injections 1Indinavir 1Immunoenzyme Techniques 1HMPL-013 1Gene Expression Profiling 1Gemcitabine 1Flow Cytometry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × Valganciclovir × Head & Neck × Clear all
NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

University of California, San Diego

Phase 2 Withdrawn
GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡